# Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms

**Authors:** Yu Ji, Hangil Lee, Shawn Kaura, James Yip, Hao Sun, Longfei Guan, Wei Han, Yuchuan Ding

PMC · DOI: 10.3390/biom11111582 · Biomolecules · 2021-10-26

## TL;DR

Bariatric surgery helps reduce obesity and related diseases like diabetes and fatty liver by altering digestion and hormone levels, though it can cause some nutritional deficiencies.

## Contribution

This review summarizes the mechanisms by which bariatric surgery improves metabolic health and highlights associated complications.

## Key findings

- Bariatric surgery reduces body mass index and improves comorbidities like T2DM and NAFLD.
- Hormonal changes, including GLP-1 and PYY, contribute to metabolic improvements after surgery.
- Complications such as osteoporosis and anemia are linked to altered nutrient absorption post-surgery.

## Abstract

Obesity is a highly prevalent public health concern, attributed to multifactorial causes and limited in treatment options. Several comorbidities are closely associated with obesity such as the development of type 2 diabetes mellitus (T2DM), cardiovascular and cerebrovascular diseases, and nonalcoholic fatty liver disease (NAFLD). Bariatric surgery, which can be delivered in multiple forms, has been remarked as an effective treatment to decrease the prevalence of obesity and its associated comorbidities. The different types of bariatric surgery create a variety of new pathways for food to metabolize in the body and truncate the stomach’s caliber. As a result, only a small quantity of food is tolerated, and the body mass index noticeably decreases. This review describes the improvements of obesity and its comorbidities following bariatric surgery and their mechanism of improvement. Additionally, endocrine function improvements after bariatric surgery, which contributes to the patients’ health improvement, are described, including the role of glucagon-like peptide-1 (GLP-1), fibroblast growth factors 19 and 21 (FGF-19, FGF-21), and pancreatic peptide YY (PYY). Lastly, some of the complications of bariatric surgery, including osteoporosis, iron deficiency/anemia, and diarrhea, as well as their potential mechanisms, are described.

## Linked entities

- **Diseases:** type 2 diabetes mellitus (MONDO:0005148), nonalcoholic fatty liver disease (MONDO:0013209), osteoporosis (MONDO:0005298), iron deficiency/anemia (MONDO:0001356)

## Full-text entities

- **Genes:** Trf (transferrin) [NCBI Gene 22041] {aka Cd176, HP, Tf, Tfn, hpx}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, FGF19 (fibroblast growth factor 19) [NCBI Gene 9965], PYY (peptide YY) [NCBI Gene 5697] {aka PYY-I, PYY1}, Fgf21 (fibroblast growth factor 21) [NCBI Gene 56636] {aka Fgf8c}, fibroblast growth factors 19 and 21 [NCBI Gene 9965;26291], APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, CCK (cholecystokinin) [NCBI Gene 885], FGF21 (fibroblast growth factor 21) [NCBI Gene 26291], CETP (cholesteryl ester transfer protein) [NCBI Gene 1071] {aka BPIFF, HDLCQ10}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, Pyy (peptide YY) [NCBI Gene 217212], CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, HSPD1 (heat shock protein family D (Hsp60) member 1) [NCBI Gene 3329] {aka CPN60, GROEL, HLD4, HSP-60, HSP60, HSP65}
- **Diseases:** liver morbidities (MESH:D017093), hypoglycemia (MESH:D007003), dumping syndrome (MESH:D004377), short bowel syndrome (MESH:D012778), adipose tissue inflammation (MESH:D007249), T2DM (MESH:D003924), insulin resistance (MESH:D007333), atherosclerosis (MESH:D050197), malabsorption phenomena (MESH:D008286), hemorrhagic stroke (MESH:D000083302), NAFLD (MESH:D065626), abnormal (MESH:D000014), Weight Loss (MESH:D015431), Diabetes (MESH:D003920), hepatic fibrosis (MESH:D008103), Metabolic Diseases (MESH:D008659), liver disease (MESH:D008107), ischemic stroke (MESH:D002544), cerebrovascular disease (MESH:D002561), loss (MESH:D016388), cirrhosis (MESH:D005355), Diarrhea (MESH:D003967), hepatic steatosis (MESH:D005234), MetS (MESH:D024821), Osteoporosis (MESH:D010024), bone fractures (MESH:D050723), inflammatory bowel disease (MESH:D015212), hypovitaminosis D (MESH:D014808), Obesity (MESH:D009765), weight gain (MESH:D015430), gallstone disease (MESH:D002769), endothelial dysfunction (MESH:D014652), myocardial infarction (MESH:D009203), Cardiovascular and Cerebrovascular Diseases (MESH:D002318), hypertension (MESH:D006973), unstable angina (MESH:D000789), anemia (MESH:D000740), Iron Deficiency and Anemia (MESH:D018798), iron deficiency (MESH:D000090463)
- **Chemicals:** creatinine (MESH:D003404), cholesterol (MESH:D002784), BA (MESH:D001647), succinate (MESH:D019802), glucose (MESH:D005947), iron (MESH:D007501), FFA (MESH:D005230), vitamin B12 (MESH:D014805), triglyceride (MESH:D014280), fat (MESH:D005223), Ca (MESH:D002118), hydrochloric acid (MESH:D006851), MUFA (MESH:D008055), alcohol (MESH:D000438), vitamin D (MESH:D014807), 25(OH) vitamin D3 (-), olive oil (MESH:D000069463)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8615605/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC8615605/full.md

## References

133 references — full list in the complete paper: https://tomesphere.com/paper/PMC8615605/full.md

---
Source: https://tomesphere.com/paper/PMC8615605